NEW YORK, Sept. 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Biohaven Ltd. (NYSE: BHVN) between March 24, 2023 and May 14, 2025, both dates inclusive (the “Class Period”), of the important September 12, 2025 lead plaintiff deadline. SO WHAT: If you purchased Biohaven securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT T ...

Core Viewpoint - A class action securities lawsuit has been filed against Biohaven Ltd. alleging securities fraud that affected investors between March 24, 2023, and May 14, 2025 [1][2]. Group 1: Lawsuit Details - The complaint claims that Biohaven Ltd. made false statements regarding the regulatory prospects of its product candidate, troriluzole, and overstated the efficacy of BHV-7000 for treating bipolar disorder [2]. - It is alleged that the misleading statements would likely have a significant negative impact on Biohaven's business and financial condition once revealed [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until September 12, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against Biohaven Ltd. alleging securities fraud that negatively impacted investors between March 24, 2023, and May 14, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Biohaven Ltd. made false statements regarding the regulatory prospects of its product candidate, troriluzole, and the efficacy of BHV-7000 for bipolar disorder, which were overstated [2]. - The complaint suggests that the revelation of these misstatements would likely have a significant negative impact on Biohaven's business and financial condition [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until September 12, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. for allegedly making materially false and misleading statements regarding its business and operations during the class period from March 24, 2023, to May 14, 2025 [2][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased or acquired Biohaven securities during the specified class period [2]. - Investors have until September 12, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The complaint alleges that Biohaven overstated the regulatory prospects of its treatment, troriluzole, for SCA, and the sufficiency of data submitted for its regulatory approval [4]. - It is also claimed that the efficacy and clinical prospects of BHV-7000 as a treatment for bipolar disorder were similarly overstated [4]. - The revelations of these overstated claims are likely to have a significant negative impact on Biohaven's business and financial condition [4]. Group 3: Contact Information - Investors who suffered losses or have questions regarding the lawsuit can contact Bragar Eagel & Squire, P.C. for more information [5][8].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Biohaven Ltd. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who bought Biohaven securities between March 24, 2023, and May 14, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by September 12, 2025 [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering hundreds of millions for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving significant recoveries in previous years, including over $438 million in 2019 [4]. Group 3: Allegations Against Biohaven - The lawsuit alleges that Biohaven made false and misleading statements regarding the regulatory prospects of its drug, troriluzole, and its efficacy for treating bipolar disorder, which were overstated [5]. - The claims suggest that the revelation of the true details would likely have a significant negative impact on Biohaven's business and financial condition, leading to investor damages [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Biohaven Ltd. securities during the specified Class Period of the upcoming lead plaintiff deadline on September 12, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Biohaven securities between March 24, 2023, and May 14, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the September 12, 2025 deadline [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. Group 3: Case Allegations - The lawsuit alleges that Biohaven made false and misleading statements regarding the regulatory prospects of its drug troriluzole for treating spinocerebellar ataxia and the efficacy of BHV-7000 for bipolar disorder, which were overstated [4]. - The lawsuit claims that these misrepresentations likely had a significant negative impact on Biohaven's business and financial condition once the truth was revealed, resulting in investor damages [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Biohaven Ltd. regarding a class action lawsuit due to alleged misleading statements and omissions related to the company's product candidates and their regulatory prospects [1][2]. Group 1: Allegations - The complaint alleges that during the class period from March 24, 2023, to May 14, 2025, Biohaven's statements regarding the regulatory prospects of its product candidate, troriluzole, were overstated [1]. - It is claimed that the efficacy and clinical prospects of BHV-7000 as a treatment for bipolar disorder were also overstated [1]. - The revelations of these issues are likely to have a significant negative impact on Biohaven's business and financial condition [1]. Group 2: Class Action Details - Shareholders who purchased shares of BHVN during the specified class period are encouraged to register for the class action, with a deadline set for September 12, 2025 [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case [2]. - There is no cost or obligation for shareholders to participate in this case [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Biohaven Ltd. securities between March 24, 2023, and May 14, 2025, of the September 12, 2025, deadline to serve as lead plaintiff in a class action lawsuit [1][2]. Group 1: Class Action Details - A class action lawsuit has been filed against Biohaven Ltd. for allegedly making false and misleading statements regarding the regulatory prospects of its drug troriluzole and the efficacy of BHV-7000 for bipolar disorder [4]. - Investors who purchased Biohaven securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [3]. - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company at the time and ranking in the top four for settlements since 2013 [3]. Group 3: Case Specifics - The lawsuit claims that Biohaven's public statements regarding the regulatory approval and clinical prospects of its drugs were materially false and misleading, which likely had a significant negative impact on the company's business and financial condition once the truth was revealed [4].

Core Viewpoint - A class action securities lawsuit has been filed against Biohaven Ltd. due to alleged securities fraud affecting investors between March 24, 2023, and May 14, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Biohaven Ltd. made false statements regarding the regulatory prospects of its product candidate, troriluzole, for treating SCA, and the sufficiency of data submitted for its regulatory approval [2]. - It is alleged that the efficacy and clinical prospects of another product, BHV-7000, for treating bipolar disorder were also overstated [2]. - The lawsuit suggests that the revelations of these misstatements would likely have a significant negative impact on Biohaven's business and financial condition [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 12, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - A shareholder class action lawsuit has been filed against Biohaven Ltd. alleging misleading statements regarding the company's business and drug prospects [1] Group 1: Allegations in the Lawsuit - The lawsuit claims that Biohaven overstated the regulatory prospects of troriluzole as a treatment for spinocerebellar ataxia [1] - It is alleged that the efficacy and clinical prospects of BHV-7000 for bipolar disorder were also overstated [1] - The lawsuit suggests that the revelation of these issues could significantly negatively impact Biohaven's business and financial condition [1] Group 2: Shareholder Information - Shareholders who purchased Biohaven shares between March 24, 2023, and May 14, 2025, and experienced significant losses are encouraged to discuss their legal rights [2] - The deadline for shareholders to request to be appointed as lead plaintiff in the case is September 12, 2025 [3] - Holzer & Holzer, LLC is noted for its representation of shareholders in litigation and has recovered hundreds of millions for victims of corporate misconduct [3]